Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

NCT05856695 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT05856695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05856695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 17, 2023
Completion date
November 30, 2028
Enrollment
67 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer extensive stage